The agreement gives Vela nonexclusive rights to use Swift’s myT® Primer technology in Vela’s real-time quantitative PCR-based IVD products for the detection of somatic mutations in human cancer.
Vela will seek regulatory approval around the world for its assay kits while Swift will continue to develop myT Primers for research-use only applications as well as license to other partners.
“By incorporating Swift’s myT Primer technology into our Real-Time PCR based molecular diagnostic products, we will provide the market with highly sensitive mutation detection capabilities which will enhance the level of cancer patient care,” says Michael Tillmann, Vela’s CEO.
David Olson, CEO, Swift Biosciences, says the agreement is part of the company's larger licensing strategy of working with partners to incorporate myT Primers to regulated in vitro diagnostics.
[Source: Swift Biosciences]